“A ruling in favor of the plaintiffs could introduce significant uncertainty into drug development,” says health expert Sally Pipes. “Each new therapy might invite claims that earlier treatments should have been replaced sooner, even when those treatments met regulatory standards at the time.”

MediaNews Group via Getty Images

This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science.

At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug.

They are not arguing that the medicine was defective, improperly manufactured, or sold without adequate warnings. Instead, they claim Gilead acted negligently by failing to bring a different, potentially safer drug to market sooner.

In other words, the case turns on a novel legal theory—that a company can be held liable not for what it made but for what it did not make quickly enough. If the courts embrace that reasoning, the implications for drug development could be profound.

To see why, it helps to understand how new medicines reach the market. Developing a new drug can take more than a decade and require billions of dollars in investment, with no guarantee of success. Researchers and companies must make decisions based on incomplete data, evolving science, and uncertain regulatory pathways.

TDF was approved by the Food and Drug Administration in 2001 and went on to become one of the most widely used HIV treatments worldwide. Like many medications, it can have side effects. Some patients have reported skin rashes and kidney- and bone-related complications—risks documented in the drug’s labeling and weighed against its substantial benefits.

In the early 2000s, Gilead also began studying a related compound known as tenofovir alafenamide, or TAF. That compound required its own development process, including years of research and clinical testing. Gilead ultimately brought TAF-based treatments to market in 2015.

The plaintiffs argue that this timeline was too slow—and that Gilead should have moved more quickly to develop and commercialize TAF.

The theory is akin to holding a technology company liable for not releasing the next generation of its product sooner. But the stakes here are far higher.

In most areas of product liability, the legal standard is relatively clear. Companies can be held responsible for defective products or inadequate warnings. This case asks courts to evaluate something far more speculative—whether a different research path, pursued on a different timeline, would have produced a better outcome.

A ruling in favor of the plaintiffs could introduce significant uncertainty into drug development. Each new therapy might invite claims that earlier treatments should have been replaced sooner, even when those treatments met regulatory standards at the time.

It could also influence how companies allocate research resources. Faced with potential liability for not moving quickly enough, firms may feel pressure to pursue multiple development pathways simultaneously—or delay bringing new drugs to market until they have explored every possible alternative.

Neither outcome is obviously beneficial for patients.

Supporters of the plaintiffs’ position suggest that liability would apply only when a company knowingly delays a safer alternative. But in practice, that is not always easy to determine.

Scientific evidence evolves over time. Early findings are often inconclusive, and promising compounds frequently fail in later-stage trials. Even when a therapy appears superior, regulatory approval is never guaranteed.

The case also highlights a broader question about the role of the judiciary. Courts are well equipped to assess whether a product was unsafe or whether warnings were inadequate. They are less well suited to evaluate the complex, iterative decisions that shape scientific research.

If liability begins to hinge on whether companies innovated “fast enough,” the incentives underpinning pharmaceutical research will shift. Investors will be less likely to fund high-risk research if the fruits of that research invite litigation.

Those changes would not be limited to a single company or a single class of drugs. They would ripple across the broader life sciences ecosystem—and ultimately lead to fewer new treatments for patients.

As the California Supreme Court considers this case this week, it will effectively decide whether courts should serve as arbiters not just of safety but of scientific timelines—a shift that could have lasting consequences for the pace of medical innovation.